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Cardiac troponins (cTn) are commonly used as diag-nostic and prognostic biomarkers1,2 and to evaluate the 
extent of myocardial necrosis in patients with acute myo-
cardial infarction (AMI). In particular, an incremental re-
lationship between risk of death and cTn levels has been 
demonstrated.1,2
In addition to the extent of myocardial necrosis, as re-
flected by cTn levels, several functional changes may occur 
during the early phase of AMI, contributing to myocardial 
cell dysfunction and ventricular impairment, thus increas-
ing morbidity and mortality. Among them, multiple lines 
of evidence suggest that mitochondria have a pivotal role 
in the pathogenesis of cell dysfunction.3,4 Indeed, the con-
traction of the heart is an energy-dependent process requir-
ing large amounts of adenosine triphosphate generated by 
mitochondrial oxidative metabolism.3,4 During ischemia 
and reperfusion, oxygen-dependent mitochondrial pro-
cesses are impaired, and this may adversely affect cellular 
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Rationale: In contrast to cardiomyocyte necrosis, which can be quantified by cardiac troponin, functional 
cardiomyocyte impairment, including mitochondrial dysfunction, has escaped clinical recognition in acute 
myocardial infarction (AMI) patients.
Objective: To investigate the diagnostic accuracy for AMI and prognostic prediction of in-hospital mortality of 
cytochrome c.
Methods and Results: We prospectively assessed cytochrome c serum levels at hospital presentation in 2 cohorts: 
a diagnostic cohort of patients presenting with suspected AMI and a prognostic cohort of definite AMI patients. 
Diagnostic accuracy for AMI was the primary diagnostic end point, and prognostic prediction of in-hospital 
mortality was the primary prognostic end point. Serum cytochrome c had no diagnostic utility for AMI (area 
under the receiver-operating characteristics curve 0.51; 95% confidence intervals 0.44–0.58; P=0.76). Among 
753 AMI patients in the prognostic cohort, cytochrome c was detectable in 280 (37%) patients. These patients 
had higher in-hospital mortality than patients with nondetectable cytochrome c (6% versus 1%; P<0.001). 
This result was mainly driven by the high mortality rate observed in ST-segment–elevation AMI patients with 
detectable cytochrome c, as compared with those with nondetectable cytochrome c (11% versus 1%; P<0.001). At 
multivariable analysis, cytochrome c remained a significant independent predictor of in-hospital mortality (odds 
ratio 3.0; 95% confidence interval 1.9–5.7; P<0.001), even after adjustment for major clinical confounders (odds 
ratio 4.01; 95% confidence interval 1.20–13.38; P=0.02).
Conclusions: Cytochrome c serum concentrations do not have diagnostic but substantial prognostic utility in AMI. 
(Circ Res. 2016;119:1339-1346. DOI: 10.1161/CIRCRESAHA.116.309792.)
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homeostasis and cardiomyocyte contraction.3,4 However, 
the clinical relevance of mitochondrial dysfunction in the 
setting of AMI is still unclear. This is mainly because of 
the lack of accurate markers able to assess mitochondrial 
function.
Cytochrome c is a water-soluble protein located in 
the inner mitochondrial membrane with an important role 
in mitochondrial energy metabolism.5 Under physiologi-
cal conditions, it localizes within the mitochondria, and it 
is not detectable in the blood of healthy human subjects.5 
Experimental models demonstrated that prolonged ischemia 
and reperfusion may predispose to mitochondrial dysfunc-
tion3,4 and cause a release of cytochrome c into the cytosol.3–5 
Moreover, elevated levels of circulating cytochrome c have 
been reported in association with cardiac arrest, chemother-
apy, fulminant hepatitis, systemic inflammatory response 
syndrome, and influenza-associated encephalopathy.6–10 All 
these conditions are characterized by critical mitochon-
dria dysfunction and release in the blood of cytochrome 
c, whose circulating levels have been demonstrated to be 
inversely related to survival outcomes. Preliminary human 
studies showed that circulating cytochrome c is also mea-
surable in the blood of patients with ST-segment–elevation 
acute myocardial infarction (STEMI).11,12 Moreover, its 
serum levels are associated with electrocardiographic and 
angiographic signs of impaired myocardial reperfusion, ex-
tension of infarct size, and 1-year mortality.11,12 Thus, cyto-
chrome c in AMI patients seems to be a potential biomarker 
of mitochondrial dysfunction that may provide diagnostic 
and prognostic information complementary to that provided 
by cTn.
The aim of this study was to better characterize the diag-
nostic and the prognostic utility of serum concentrations of 
cytochrome c in AMI.
Methods
Population of the Diagnostic Cohort
Patients presenting to the Emergency Department of the University 
Hospital of Basel, Switzerland, with symptoms suggestive of AMI 
were recruited (Online Data Supplement). Patients with kidney fail-
ure requiring dialysis were excluded. For this analysis, also patients 
with STEMI or with an unknown diagnosis after adjudication and at 
least 1 elevated high-sensitivity (hs)-cTnT level possibly indicating 
AMI were excluded.
Population of the Prognostic Cohort
Patients with definite AMI (STEMI and non-STEMI [NSTEMI]) 
admitted to the Centro Cardiologico Monzino, Milan, Italy, were 
prospectively considered eligible for enrollment. The only ex-
clusion criterion was lack of informed consent. The study was 
performed according to the principles of the Declaration of 
Helsinki; the ethics committee of the Institute approved the study; 
and all patients gave written consent to use part of their blood for 
scientific purposes.
Study Protocol
In all patients, peripheral venous blood was drawn at hospital ad-
mission to measure hs-cTnT (diagnostic cohort), cTnI (prognostic 
cohort), serum cytochrome c, and standard biochemical parameters. 
Moreover, in the prognostic cohort, we measured circulating cell–free 
mitochondrial DNA (mtDNA), a biomarker that has been associated 
with survival in critically ill patients.13
In-hospital outcomes and 1-year mortality were assessed for all 
patients included in the prognostic cohort. Patient follow-up was ob-
tained through regularly scheduled outpatient visits or by telephone 
contacts performed by dedicated medical personnel.
Diagnostic accuracy for AMI was the primary end point in 
the diagnostic cohort, and prognostic prediction for in-hospital 
mortality was the primary end point in the prognostic cohort. 
The following secondary end points were considered in the prog-
nostic cohort: (1) the combination of in-hospital mortality, acute 
pulmonary edema requiring mechanical ventilation, and cardio-
genic shock requiring intra-aortic balloon pump; and (2) 1-year 
mortality.
Laboratory Assays
In the diagnostic cohort, hs-cTnT (ng/L) was measured by an elec-
trochemiluminescence immunoassay (ECLIA, Roche Elecsys 2010 
hs-cTnT).
In the prognostic cohort, cTnI (ng/mL) was measured by a 2-site 
immune-enzymatic (sandwich) chemiluminescent technique, using 
the UniCell DXI 800 (Beckman Coulter, Fullerton, CA).
In both the diagnostic and prognostic cohorts, cytochrome c (ng/
mL) was measured in the serum at hospital admission by ELISA, 
using a commercially available enzyme-linked immunosorbent assay 
(Quantikine; R&D System Inc, Minneapolis, MI), as previously de-
scribed (Online Data Supplement).12 The lowest detection limit was 
0.08 ng/mL. Circulating levels of mtDNA were measured in the se-
rum, as reported by Nakahira et al.14
Statistical Analysis




From March 26, 2008, to July 8, 2009, a total of 418 patients 
presenting with symptoms suggestive of AMI were recruited 
(Online Figure I and Table I).
The diagnostic accuracy of hs-cTnT at admission in the 
diagnosis of AMI, as quantified by the area under the curve, 
was 0.94 (95% confidence intervals 0.92–0.97), which was 
significantly higher than that of cytochrome c at admission 
(area under the curve 0.51; 95% confidence interval 0.44–
0.58; P<0.001 for comparison). Moreover, the combination of 
the 2 markers did not improve the diagnostic accuracy com-
pared with hs-cTnT alone (area under the curve 0.94; 95% 
confidence interval 0.92–0.97; P=0.10 for comparison; Online 
Figure II). hs-cTnT plus cytochrome c provided a net reclas-
sification improvement of 4.2% (P=0.18) and an integrated 
discrimination improvement of 1% (P<0.001) in AMI diagno-
sis, when compared with hs-cTnT alone.
Prognostic Cohort
From June 1, 2010, to September 30, 2012, a total of 753 pa-
tients with a diagnosis of definite AMI (316 STEMI and 437 
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NSTEMI non–ST-segment–elevation myocardial infarction
STEMI ST-segment–elevation acute myocardial infarction
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NSTEMI) were consecutively enrolled (Online Figure III). At 
hospital admission, cytochrome c was detectable in the blood 
of 280 (37%) patients. Table shows the demographic and 
clinical characteristics of patients with detectable and nonde-
tectable cytochrome c. These 2 groups were comparable for 
all evaluated variables. The only observed significant differ-
ence between AMI patients with detectable cytochrome c and 
those without detectable cytochrome c was in mtDNA levels 
(290 [142–490] copies/μL versus 210 [22–362] copies/μL; 
P=0.003). Clinical characteristics of the 2 groups were also 
similar when STEMI and NSTEMI patients were analyzed 
separately (Online Table II).
In-hospital mortality and combined end point rates were 
significantly higher in patients with detectable cytochrome c 
than in those without detectable cytochrome c (Online Table 
III). These results were mainly driven by the high rates ob-
served in STEMI patients with detectable cytochrome c as 
compared with those with nondetectable cytochrome c. A 
significant gradient of increasing incidence of in-hospital 
mortality and of the combined end point was observed going 
from patients with nondetectable cytochrome c to those with 
detectable cytochrome c below the median value and ending 
with those with a detectable cytochrome c above the median 
value. Again, this trend was particularly evident in STEMI 
patients (Figure 1).
The correlations between cytochrome c and cTnI, hs-C-
reactive protein, and mtDNA are reported in the Online Table 
IV, while their distribution in patients who died versus those 
who survived is shown in the Online Figure IV.
Cumulative 1-year mortality was higher in patients with 
detectable cytochrome c than in those without detectable cy-
tochrome c (Online Table III). The Kaplan–Meier curves for 









Age, y 66±13 67±13 0.23
Male sex, n (%) 200 (71) 344 (73) 0.70
STEMI, n (%) 128 (45) 188 (40) 0.11
Body mass index, kg/m2 26.7±4.5 26.7±4.3 0.96
Diabetes mellitus, n (%) 60 (21) 112 (24) 0.47
Hypertension, n (%) 175 (62) 305 (64) 0.58
Dyslipidemia, n (%) 139 (50) 247 (52) 0.51
Smokers, n (%) 143 (51) 267 (56) 0.15
Prior myocardial  
infarction, n (%)
79 (28) 119 (25) 0.35
Prior CABG, n (%) 38 (14) 51 (11) 0.25
Prior PCI, n (%) 69 (25) 115 (24) 0.91
Left ventricular ejection 
fraction,* %
51±13 52±12 0.23
Time-to-treatment, h 3.5 (2–10) 4 (2–10) 0.93†
TIMI risk score 4.3±2.3 4.2±2.2 0.55
In-hospital treatment, n (%)
  PCI 223 (80) 356 (75) 0.16
  CABG 11 (4) 8 (6) 0.23
  Medical therapy 46 (16) 89 (19) 0.40
Infarct related artery, n (%)   0.90
  Left anterior descending 86 (33) 156 (36)  
  Right coronary artery 64 (25) 94 (22)  
  Left circumflex 60 (23) 98 (23)  
  Bypass graft 12 (5) 10 (5)  
  Left main 7 (3) 20 (2)  
Laboratory values
  Blood glucose, mg/dL 130 (110–172) 128 (108–169) 0.48†
  Serum creatinine, mg/dL 0.9 (0.8–1.1) 0.9 (0.8–1.1) 0.64†
  eGFR, mL/min per  
1.73 m2
82±27 85±31 0.41
  Baseline  
troponin I, ng/mL
0.8 (0.2–3.3) 0.6 (0.1–2.1) 0.018†
  Peak troponin I, ng/mL 6.2 (1.4–45.6) 6·1 (1.2–32.3) 0.26†
  Hemoglobin, g/dL 13.5±2 13.5±2 1.0
  Total cholesterol, mg/dL 181±49 181±46 0.82
  HDL, mg/dL 39±11 40±12 0.36
  LDL, mg/dL 118±45 115±42 0.33
  Triglycerides, mg/dL 125±85 130±78 0.45
  hs-CRP, ng/mL 3.2 (1.3–10.7) 3.8 (1.4–14.7) 0.30†
Medication at hospital admission, n (%)
  Aspirin 202 (72) 330 (70) 0.49
(Continued )
  ACE/ARB 117 (42) 208 (44) 0.55
  Beta-blockers 105 (37) 175 (37) 0.89
  Statins 95 (34) 162 (34) 0.92
  Warfarin 12 (4) 21 (4) 0.92
Medication at hospital discharge, n (%)
  Aspirin 255 (96) 451 (96) 0.82
  ACE/ARB 163 (61) 292 (64) 0.51
  Beta-blockers 193 (72) 333 (72) 0.97
  Statins 234 (88) 407 (89) 0.74
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; CABG, coronary artery bypass graft; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity 
C-reactive protein; LDL, low-density lipoprotein; LVEF, left ventricular ejection 
fraction; PCI, percutaneous coronary intervention; STEMI, ST-segment–
elevation myocardial infarction; and TIMI, Thrombolysis In Myocardial 
Infarction.
*LVEF was measured by echocardiography at hospital admission in all 
patients (before or soon after primary PCI in STEMI).
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1-year mortality in the entire prognostic cohort, as well as in 
STEMI and NSTEMI patients analyzed separately, are shown 
in Figure 2. Again, the prognostic impact of cytochrome c was 
observed in STEMI patients only, and it was limited to the first 
30 days, as demonstrated by the landmark analysis (Online 
Figure V).
At multivariable analysis, cytochrome c remained a sig-
nificant independent predictor of in-hospital mortality, even 
after adjustment for major recognized determinants of mortal-
ity in AMI (Online Table V). When cytochrome c and cTnI 
at hospital admission were considered together in the entire 
population, a complementary predictive value on mortality 
was found (Figure 3).
Discussion
The main finding of this study was that, despite its lack of 
utility for diagnosis, cytochrome c at hospital admission is 
strongly associated with in-hospital mortality in AMI. The 
prognostic power of cytochrome c is particularly evident in 
STEMI patients, and it was independent of clinical variables 
that are known to affect AMI outcome.
The mechanisms involved in ventricular impairment dur-
ing the early phase of AMI are not completely elucidated. 
Growing evidence suggests that functional processes may be 
implicated in addition to the extent of myocardial necrosis. 
Although myocardial necrosis may be estimated by enzy-
matic release,1,2 the amount of functional impairment cannot 
be easily assessed in clinical practice. Ischemia and reper-
fusion phenomena cause intracellular calcium overload and 
generation of reactive oxygen species,4 which predispose to 
mitochondrial dysfunction, and may contribute, in addition 
to cell necrosis, to myocardial contractility impairment.3,4 
Apart from the underlying mechanism, impairment of mi-
tochondrial function is followed by cytochrome c release 
which, therefore, can be considered a marker of mitochon-
drial dysfunction.5–10
In our study, we measured circulating cytochrome c at 
hospital admission in patients with suspected and definite 
Figure 1. In-hospital mortality (blue 
bars) and combined end point (red 
bars) rates in the entire prognostic 
cohort (A), in ST-segment–elevation 
myocardial infarction (STEMI) patients 
(B), and in non-STEMI (NSTEMI) patients 
(C), grouped according to serum 
cytochrome c value (nondetectable vs 
detectable below the median value vs 
detectable above the median value). 
*Median value refers to that of the 
prognostic cohort. The P values within 
the blue boxes refer to P for trend for in-
hospital mortality, while the P values within 
the red boxes refer to P for trend for the 
combined end point.
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AMI to characterize its diagnostic and prognostic utility. 
Although it has no diagnostic accuracy, we found a striking 
association between the levels of this protein and in-hospi-
tal cardiac mortality and morbidity in patients with AMI. 
Notably, we observed a 10-fold higher in-hospital mortality 
in STEMI patients when cytochrome c was detected, despite 
similar baseline risk profile, drug treatment, and mechanical 
reperfusion rate between patients with or without detectable 
cytochrome c. In NSTEMI patients in whom cytochrome c 
was detected, a 2-fold higher in-hospital mortality rate was 
observed. However, the mortality difference between them 
and NSTEMI patients without detectable cytochrome c did 
not reach statistical significance. Although we cannot deduce 
from our study the reasons behind this, we can speculate that 
the low number of in-hospital events and the smaller ischemic 
involvement, both characterizing NSTEMI, may explain this 
result.
Several findings of our study indicate that cytochrome c 
detection in the blood may be a marker of acute left ventricle 
impairment beyond that because of myocardial necrosis. 
First, unlike cTn, cytochrome c did not help to diagnose AMI 
in patients presenting with chest pain. Notably, cytochrome 
c was detected in 66% of patients without AMI included in 
the diagnostic cohort, and no correlation was found between 
cytochrome c and either admission or peak cTnI in the prog-
nostic cohort. Second, cytochrome c predicted in-hospital 
mortality independently of cTnI value at admission. Third, 
despite similar left ventricular ejection fraction at admission 
and cTnI peak value, death was in most cases because of he-
modynamic complications, as shown by a higher incidence 
Figure 2. Kaplan–Meier curves 
according to serum cytochrome c 
detection at hospital admission in 
the entire prognostic cohort (A), in 
ST-segment–elevation myocardial 
infarction (STEMI) patients (B), and 
in non-STEMI (NSTEMI) patients (C). 
P value =Log-rank test.
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of cardiogenic shock and acute pulmonary edema in patients 
with detectable cytochrome c. Finally, the prognostic rele-
vance of cytochrome c was evident in the early phase of AMI 
because the survival curves of STEMI patients with or with-
out detectable cytochrome c showed a parallel trend after 30 
days. Therefore, combining the measurement of cTn and cy-
tochrome c at hospital admission may provide independent 
and complementary prognostic information, considerably 
improving early risk stratification of AMI patients.
How cytochrome c reaches the bloodstream is not well 
understood and cannot be inferred from our data. Similarly, 
the mechanisms underlying the association between cy-
tochrome c and a worse outcome in the clinical setting of 
AMI remain unclear. Several studies showed that the release 
of cytochrome c outside the cell occurs without concomitant 
release of larger molecules, such as lactate dehydrogenase, 
which is considered a marker of cell necrosis.7 This suggests 
that in parallel with myocardial necrosis, cardiac cells that 
are still viable may be only functionally impaired because of 
mitochondrial dysfunction.
Based on these considerations, our study suggests that 
circulating cytochrome c may be a biomarker of mitochondri-
al dysfunction and may be used to prognosticate survival in 
AMI patients. Similar findings were obtained in animal stud-
ies and preliminary clinical reports performed in small se-
ries of patients with other critical conditions. Radhakrishnan 
et al15 reported a rise in plasma cytochrome c levels in an 
experimental model of cardiac arrest, with higher levels in 
the rats that did not survive. Serum cytochrome c showed a 
similar predictive value of poor prognosis in patients with 
systemic inflammatory response syndrome, causing multi-
organ failure,7 influenza-associated encephalopathy,9 and 
fulminant hepatitis.8 Thus, unlike cTn, cytochrome c is not 
a specific marker of cardiac cell injury; instead, it seems to 
be a sensitive marker of mitochondrial dysfunction occur-
ring in organs that are rich in mitochondria and have a high 
Figure 3. In-hospital mortality odds 
ratio ([OR] and 95% confidence 
intervals [CI]; A) and 1-year mortality 
hazard ratio ([HR]; and 95% CI; B) 
in the entire prognostic cohort, 
grouped according to cardiac 
troponin I (cTnI) value (<or ≥ median 
value) and cytochrome c at hospital 
admission. *cTnI median value of the 
entire prognostic cohort. OR, P value 
=logistic regression analysis; HR,  
P value =Cox regression analysis.
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metabolic rate with propensity to ischemia and reperfusion 
injury. Indeed, we cannot exclude that cytochrome c increase 
is caused by systemic hypoperfusion in organs other than the 
heart. Notably, we found significantly higher mtDNA levels 
at hospital admission in AMI patients with detectable cyto-
chrome c, supporting the hypothesis of cytochrome c release 
from the mitochondria. However, mtDNA did not correlate 
with cytochrome c and, differently from other critical set-
tings,13,14 it was not associated with mortality. The lack of 
an mtDNA prognostic relevance in our study might be ex-
plained by the different clinical setting (AMI) and the early 
mtDNA assessment (soon after AMI onset), when compared 
with previous reports.13,14 Future studies are warranted to 
specifically investigate the role of mtDNA in AMI patients.
Our findings may have some relevant clinical implications. 
Cytochrome c measurement at admission may be used to iden-
tify high-risk patients who cannot be recognized only on the 
basis of the current clinical variables. Indeed, novel thera-
peutic strategies in addition to standard pharmacological and 
interventional treatments could be used for improving the out-
come of AMI patients who have detectable cytochrome c. In 
particular, cardioprotective pharmacological and mechanical 
therapies supporting ventricular contractility without increas-
ing oxygen consumption, such as levosimendan or intra-aortic 
counterpulsation, and preserving mitochondrial integrity and 
function, like cyclosporine A, metformin, and other manipu-
lating mitochondrial agents, should be investigated.
In interpreting our data, some limitations should be con-
sidered. First, the diagnostic cohort was relatively small. 
Second, the global applicability of our prognostic findings 
remains uncertain, and it should be validated in a larger 
multicenter study. Third, our data generate hypotheses only 
because they do not provide evidence to support direct mech-
anisms underlying the connection between cytochrome c and 
mortality nor myocardial dysfunction. In particular, the se-
rial assessment of ventricular function after AMI could help 
to clarify the link between cytochrome c and acute cardiac 
functional impairment. Moreover, experimental data are re-
quired in suitably designed models to explore the specific 
mechanism(s) inducing cytochrome c release, as well as 
its biological meaning. Finally, we did not serially evaluate 
cytochrome c levels in our AMI patients. Because most of 
them underwent emergency or urgent percutaneous coronary 
revascularization, we cannot exclude that cytochrome c mea-
surement performed also after the procedure, instead of at-
hospital admission only, could have increased its prognostic 
potential by incorporating mitochondrial damage associated 
with mechanical reperfusion injury. Indeed, a further increase 
of circulating cytochrome c has been shown in STEMI pa-
tients undergoing primary percutaneous intervention.12
 Of 
note, its peak value was associated with impaired myocar-
dial reperfusion and 1-year mortality.11,12 Nevertheless, cyto-
chrome c measurement at hospital admission allowed us to 
distinguish 2 groups of patients with a similar risk profile but 
with a strikingly different prognosis.
In conclusion, our study demonstrated that circulating cy-
tochrome c detected at hospital admission does not have diag-
nostic but substantial prognostic utility in AMI, particularly 
in STEMI. Therefore, cytochrome c could be considered a 
potential biomarker of mitochondrial dysfunction that may in-
tegrate markers of necrosis to predict patients’ survival.
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What Is Known?
•	 Impaired mitochondrial function in ischemic myocardium plays a criti-
cal role in cardiac dysfunction post acute myocardial infarction (AMI).
•	 Cytochrome c is a mitochondrial protein that can be found in the blood 
of critically ill patients.
What New Information Does This Article Contribute?
•	 Detection of cytochrome c in the blood at hospital admission is associ-
ated with higher in-hospital mortality in patients with AMI.
In patients with a bout of AMI, cell necrosis and stunning lead 
to cardiac remodeling. The former can be accurately detected 
by measuring plasma levels of troponins, while the currently 
available markers cannot accurately assess the latter. We show 
that detection of circulating cytochrome c, a marker for mito-
chondrial damage, was associated with increased in-hospital 
mortality, independent of other risk factors, drug treatment, me-
chanical reperfusion rate, and peak troponin values. Circulating 
cytochrome c is associated with poor prognosis in other criti-
cally ill settings. However, to our knowledge, this is the first study 
demonstrating the independent prognostic value of circulating 
cytochrome c in AMI. Thus, detection of cytochrome c might com-
plement troponin assays in evaluation of prognosis in patients 
with AMI. Future studies are warranted to confirm our findings 
and elucidate the potential mechanisms underlying the associa-
tion between circulating cytochrome c and a worse outcome in 
patients with AMI.
Novelty and Significance
